BAIT
CD22
SIGLEC-2, SIGLEC2
CD22 molecule
GO Process (0)
GO Function (1)
GO Component (1)
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
JAK3
JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK
Janus kinase 3
GO Process (30)
GO Function (5)
GO Component (2)
Gene Ontology Biological Process
- B cell differentiation [IBA, ISS]
- JAK-STAT cascade involved in growth hormone signaling pathway [TAS]
- STAT protein import into nucleus [TAS]
- T cell homeostasis [IBA, ISS, TAS]
- cell migration [IBA]
- enzyme linked receptor protein signaling pathway [ISS]
- erythrocyte differentiation [IBA]
- inflammatory response [IBA]
- innate immune response [IBA]
- interleukin-4-mediated signaling pathway [IDA]
- intracellular signal transduction [ISS]
- negative regulation of FasL biosynthetic process [ISS]
- negative regulation of T cell activation [ISS]
- negative regulation of T-helper 1 cell differentiation [ISS]
- negative regulation of dendritic cell cytokine production [ISS]
- negative regulation of interleukin-10 production [ISS]
- negative regulation of interleukin-12 production [ISS]
- negative regulation of thymocyte apoptotic process [ISS]
- peptidyl-tyrosine autophosphorylation [IBA]
- peptidyl-tyrosine phosphorylation [ISS]
- positive regulation of T cell proliferation [IBA]
- protein phosphorylation [TAS]
- regulation of T cell apoptotic process [ISS]
- regulation of apoptotic process [IBA]
- response to interleukin-15 [TAS]
- response to interleukin-2 [TAS]
- response to interleukin-4 [IDA]
- response to interleukin-9 [TAS]
- transmembrane receptor protein tyrosine kinase signaling pathway [IBA]
- tyrosine phosphorylation of STAT protein [IBA, TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions.
Identification of effective combination therapies is critical to address the emergence of drug-resistant cancers, but direct screening of all possible drug combinations is infeasible. Here we introduce a CRISPR-based double knockout (CDKO) system that improves the efficiency of combinatorial genetic screening using an effective strategy for cloning and sequencing paired single guide RNA (sgRNA) libraries and a robust statistical scoring ... [more]
Nat. Biotechnol. Mar. 20, 2017; 0(); [Pubmed: 28319085]
Quantitative Score
- -3.221 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: growth abnormality (HP:0001507)
Additional Notes
- CRISPR GI screen
- Cell Line:K562 (EFO:0002067)
- Experimental Setup:Timecourse
- GIST: A-phenotypic negative genetic interaction
- Library:Drug Target-CDKO CRISPRn library
- Significance Threshold: q-value<0.05
Curated By
- BioGRID